About Reneo Pharmaceuticals
Reneo Pharmaceuticals is a publicly listed company based in San Diego (United States) founded in 2015. Small molecule therapies for orphan diseases are being developed. Reneo Pharmaceuticals has raised $145 million across 2 funding rounds from investors including Abingworth, Novo Holdings and NEA. The company has 48 employees. Its chief executive, as recorded, is Gregory J Flesher. Its focus areas include Life Sciences, Immunology, Drugs and Fibrosis. Its legal entity is RENEO PHARMACEUTICALS, INC. Its competitors include Sionna, Blade Therapeutics and Arcturus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Reneo Pharmaceuticals was founded in 2015 in San Diego, United States, within the biopharmaceutical sector. Efforts are directed toward creating treatments for orphan diseases, with small molecules such as PPAR agonists aimed at rare genetic disorders. A drug candidate for fibrosis treatment is currently advancing through clinical trials. Operations emphasize research and development in this specialized field.
- Headquarters San Diego, United States
- Employees 48
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website reneopharma.com
- Social LinkedIn
- Legal Name Reneo Pharmaceuticals, Inc.
- Net Profit-$77.39 M (USD)-49as on Dec 31, 2023
- EBITDA-$83.05 M (USD)-54as on Dec 31, 2023
- Total Equity Funding$145M (USD)
in 2 rounds
- Latest Funding Round$95M (USD), Series B
Dec 2020
- InvestorsAbingworth
& 8 more
- Employee Count48
Funding Insights of Reneo Pharmaceuticals
Reneo Pharmaceuticals has successfully raised a total of $145M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $95 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $145M
- Total Rounds 2
- Last Round Series B — $95M
- First Round $50M
(May 2019)
- Investors Count 9
All 2 funding rounds of Reneo Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $95M | Series B | – | Novo Holdings, Abingworth | |
| May 2019 | $50M | Series A | – | New Enterprise Associates |
9 investors in total: 9 institutional.
Investors in Reneo Pharmaceuticals
Reneo Pharmaceuticals has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Abingworth, Novo Holdings and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
| rivervest.com | ||||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Life science companies are funded through venture capital investments. | lundbeckfonden.com | Copenhagen, Denmark | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Amzak Health is engaged in venture investments in life sciences. | amzakhealth.com | New York, United States |
Investor details for Reneo Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Reneo Pharmaceuticals
17 people are tracked at Reneo Pharmaceuticals (7 in leadership, 9 in board & advisors, 1 in team); the tracked headcount is 48.
| Name | Role | Group |
|---|---|---|
Gregory J Flesher | CEO | Leadership |
Ashley F. Hall | Chief Development Officer | Leadership |
Michael Cruse | COO | Leadership |
Alejandro Dorenbaum | Chief Medical Officer | Leadership |
Aneta Ferguson | Vice President, Head Of Global Legal Affairs | Leadership |
Ricardo Graham | Director Of Information Technology | Leadership |
Maggie Loeffler, CPA | Executive Director OF Financial Reporting AND Technical Accounting | Leadership |
Bali Muralidhar | Director | Board & advisors |
Scott Weiner | Director | Board & advisors |
Eric Dube | Director | Board & advisors |
Arthur Pappas | Director | Board & advisors |
Mike Grey | Executive Chairman | Board & advisors |
Niall O’Donnell | Director | Board & advisors |
Stacey D. Seltzer | Director | Board & advisors |
Roshawn Blunt | Director | Board & advisors |
Ed Mathers | Director | Board & advisors |
Lynn Purkins | SVP, Clinical Operations | Team |
Complete people profiles for Reneo Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Reneo Pharmaceuticals
4 dated milestones of Reneo Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Reneo Pharmaceuticals is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series B, of $95.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Reneo Pharmaceuticals
Reneo Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Sionna, Blade Therapeutics and Arcturus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sionnatx.com | 2019 | Natick, United States | $293M | Small molecule therapeutics for cystic fibrosis are developed. | ||
| blademed.com | 2015 | San Francisco, United States | $93M | 30 | Antifibrotic strategies are developed for congenital and acquired fibrotic diseases. | |
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. |
Detailed competitors of Reneo Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Reneo Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reneo Pharmaceuticals
Complete news archive for Reneo Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reneo Pharmaceuticals
Reneo Pharmaceuticals was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Reneo Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Gregory J Flesher is the CEO of Reneo Pharmaceuticals, as recorded in our data.
Reneo Pharmaceuticals is a funded company, having raised a total of $145M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on May 2019.
Reneo Pharmaceuticals has 48 employees.
Reneo Pharmaceuticals was founded in 2015 in San Diego, United States, within the biopharmaceutical sector. Efforts are directed toward creating treatments for orphan diseases, with small molecules such as PPAR agonists aimed at rare genetic disorders. A drug candidate for fibrosis treatment is currently advancing through clinical trials. Operations emphasize research and development in this specialized field.
Reneo Pharmaceuticals's top competitors include Arcturus Therapeutics, Sionna and Blade Therapeutics.
Reneo Pharmaceuticals has 9 investors. Key investors include Abingworth, Novo Holdings, NEA, Pappas Capital, and RiverVest Venture Partners.
Reneo Pharmaceuticals operates through Reneo Pharmaceuticals, Inc..